L3VLUP
ProSign in

ALLO · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ALLOAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ALLO
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterALLOAMGN
Q3 20209 holders, $702m16 holders, $16.3bn
Q4 20205 holders, $462m19 holders, $14.0bn
Q1 20217 holders, $666m16 holders, $14.5bn
Q2 20218 holders, $321m23 holders, $13.8bn
Q3 20215 holders, $302m24 holders, $11.6bn
Q4 20213 holders, $10m21 holders, $10.4bn
Q1 20223 holders, $6.5m23 holders, $9.9bn
Q2 20223 holders, $79m28 holders, $9.7bn
Q3 20224 holders, $60m21 holders, $7.9bn
Q4 20222 holders, $26m24 holders, $9.3bn
Q1 20232 holders, $11m22 holders, $8.4bn
Q2 20232 holders, $27m26 holders, $7.4bn
Q3 20233 holders, $18m26 holders, $8.7bn
Q4 20232 holders, $11m24 holders, $8.4bn
Q1 20243 holders, $15m25 holders, $6.7bn
Q2 20243 holders, $27m20 holders, $8.0bn
Q3 20244 holders, $37m21 holders, $8.8bn
Q4 20243 holders, $24m20 holders, $8.2bn
Q1 20252 holders, $24m25 holders, $12.0bn
Q2 20251 holders, $13m20 holders, $10.2bn
Q3 2025none listed holders, n.a.17 holders, $10.4bn
Q4 2025none listed holders, n.a.19 holders, $18.0bn
Q1 2026none listed holders, n.a.15 holders, $21.4bn
Q2 2026none listed holders, n.a.23 holders, $24.9bn
ALLO

Allogene Therapeutics Inc

Holders
3
Reported value
$24m
Buyers
0
Sellers
2

Breadth -2 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
20
Reported value
$8.2bn
Buyers
13
Sellers
7

Breadth +6 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2024

Among the 20 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ALLO (0)

None.

Only AMGN (17)

AllianceBernstein LP, ARK Investment Management LLC, Capital Research Global Investors, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, PDT Partners LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →